Safety/Efficacy Study With Armodafinil (CEP-10953) in Treatment of Excessive Sleepiness Associated With Chronic SWSD

NCT00080288 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

254

Enrollment

INDUSTRY

Sponsor class

Conditions

Excessive Sleepiness
Shift Work Sleep Disorder

Interventions

DRUG: Armodafinil 150 mg/day
DRUG: Placebo

Sponsor

Cephalon